REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies to treat cancer today announced the appointment of Laura Berner. to the Board effective December 14, 2022.
Dr. Randall Schatzman, CEO of Bolt Biotherapeutics, said: “As we continue to advance our immuno-oncology pipeline program in our clinics, Laura has been a key player in leading and executing over 50 transactions, including research collaborations, product co-development and co-promotion partnerships. I am excited to have her join our board.”
“Powered by the breakthrough Boltbody™ ISAC technology, Bolt is developing a transformative immunotherapy pipeline with the potential to improve patient lives and make a meaningful impact in the fight against cancer. ‘ said Berner. “I am honored to be joining the Board of Directors of Volt. We look forward to supporting the advancement of the ISAC platform.”
Laura Berner has extensive experience in the biopharmaceutical industry and has held leadership roles spanning corporate strategy, business development, investor relations and legal. She currently serves as Chief Operating Officer of TRexBio, a private venture-backed biotechnology company, where she is responsible for corporate and operational functions. Prior to that, she was Vice President and Head of Business Development and Investor Relations at Myovant Sciences, where she led a global partnership to commercialize the company’s flagship product, Myfembree. led the execution of® (relugolix, estradiol and norethindrone acetate) and Orgovyx® (relugolix) and supported Myovant through multiple additional funding rounds. Early in his career, Mr. Berner was a member of his business development team at Roche Pharma Partnering and he was a member of Genentech’s trade law group. He began his career as a corporate attorney, first at Ropes & Gray LLP and later at Harvard University’s Office of the General Counsel, advising on general corporate, business development, and strategic transactions. Mr. Berner holds a BA in Biology from Bryn Mawr College, a LL.B. from Stanford Law School, and his MBA from the University of Illinois Urbana Champagne Gies College of Business.
About Volt Biotherapeutics
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates build on the company’s deep expertise in bone marrow biology and anticancer drug development. Bolt Biotherapeutics’ pipeline includes BDC-1001, a Boltbody immunostimulatory antibody conjugate (ISAC) targeting HER2, BDC-3042, a myelomodulatory antibody, and multiple Boltbody ISAC collaboration programs. Bolt Biotherapeutics is currently advancing his BDC-1001 through a Phase 1/2 dose escalation clinical trial as monotherapy and in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor Opdivo.® (nivolumab), in a variety of HER2-expressing solid tumors. Bolt Biotherapeutics is advancing BDC-3042, an agonistic antibody targeting Dectin-2, through IND-enabled studies. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supporting macrophages into tumor-destroying macrophages. Bolt Biotherapeutics leverages Boltbody ISAC’s ability to design and optimize new applications to develop multiple immuno-oncology candidates through strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.
This press release contains forward-looking statements regarding our company and our industry that are subject to significant risks and uncertainties and are based on our beliefs and assumptions and information currently available. All statements other than statements of historical fact contained in this press release, including statements regarding our clinical trials, successful collaborations and our application of his ISAC platform, are forward-looking statements. In some cases, we use terms such as “predict”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “on track”, etc. The language is included to identify forward-looking statements. “plan”, “could”, “predict”, “plan”, “should”, “will”, or “would”, or the negative of any of these words, or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors and actual results, performance or achievements may not be expressed or implied by the forward-looking statements. may differ materially from the results, performance or achievements of Forward-looking statements represent our current views, estimates and assumptions as of the date of this press release only, and the information contained in this press release is relied upon as representing our estimates as of any subsequent date. should not be. These statements and the associated risks, uncertainties, factors and assumptions include, but are not limited to: Clinical trials may not confirm the safety, efficacy or other product characteristics described or contemplated in this press release. Such product candidates may not be beneficial to patients or may not be commercialized. Ability to maintain current collaborations and establish further collaborations. These risks are not exhaustive. We may not update these forward-looking statements or cause actual results to differ materially from those projected in the forward-looking statements, even if new information becomes available in the future, except as required by law. We are not obligated to update or update the reasons for possible differences. Further information regarding factors that could cause actual results to differ materially from those anticipated by our forward-looking statements is available from the United States Securities and Exchange Commission, including our annual report on Form 10-K. It is included in the report submitted or to be submitted to the meeting. Year ending December 31, 2021.
INVESTOR INFORMATION AND MEDIA CONTACTS
Karen L. Bergman
Vice President of Communications and Investor Relations
Volt Biotherapeutics, Inc.
Stern Investor Relations, Inc.
Russo Partners, LLC